Citius Pharmaceuticals, Inc.
CTXR
$0.968
-$0.021-2.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.74% | 3.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.15% | 3.91% | |||
| Operating Income | 9.15% | -3.91% | |||
| Income Before Tax | 8.38% | -4.83% | |||
| Income Tax Expenses | 83.47% | 0.00% | |||
| Earnings from Continuing Operations | 7.19% | -4.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 78.75% | -- | |||
| Net Income | 9.47% | -2.05% | |||
| EBIT | 9.15% | -3.91% | |||
| EBITDA | 9.15% | -3.92% | |||
| EPS Basic | 18.10% | -1.61% | |||
| Normalized Basic EPS | 15.23% | 3.46% | |||
| EPS Diluted | 23.42% | -8.66% | |||
| Normalized Diluted EPS | 15.23% | 3.46% | |||
| Average Basic Shares Outstanding | 3.57% | 4.03% | |||
| Average Diluted Shares Outstanding | 3.57% | 4.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||